SCHEMBL7138155

SCHEMBL7138155

CCCCCN(C(C)=O)S(=O)(=O)[C@H](OCc1ccccc1)N(CC(C)CC)C(=O)OCc1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CCR6 P51684 1/20 0.34
PAX8 Q06710 1/20 0.34
CCR5 P51681 1/20 0.34
CTRC Q99895 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
CTSL P07711 1/20 0.33
CTSS P25774 1/20 0.33
CETP P11597 3/20 0.33
CCKBR P32239 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7140769 0.87 CA12 (0.38) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL7798654 0.80 CA12 (0.41)
SCHEMBL20147821 0.72 ALDH1A1 (0.44) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL7138159 0.72 CCR6 (0.38) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL20794168 0.71 ALDH1A1 (0.49) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL28110794 0.71 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL20147826 0.70 ALDH1A1 (0.50) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL30744367 0.70 CETP (0.46) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL7132828 0.69 ALDH1A1 (0.39) ALDH1A1CYP3A4TSHRMAPK1TDP1
SCHEMBL27990536 0.67 CCR6 (0.66) ALDH1A1CYP3A4TSHRMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030092634-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2003-05-15 US disclosed
US-6506733-B1 Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. AXYS PHARMACEUTICALS, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092634-A1 Novel compounds and compositions as protease inhibitors SERPINB1, HPN, CTRL ALDH1A1 3641/4885CYP3A4 1171/4885TSHR 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.